In a related article, Steadman and colleagues (pages 732 to 738) describe a pilot study in which they used a selective 5-hydroxytryptamine type 3 receptor antagonist
Serotonin (5-Hydroxytryptamine or 5-HT) has long been postulated to play a major role in gut function, since its initial isolation and localization to enteroendocrine cells by
Ondansetron can be used as a highly specific and selective serotonin 5-HT3receptor antagonist for reducing the small and large intestinal motility in donkeys, and is
27 to $0
Multiday administration of ondansetron has been shown to slow colonic transit in normal volunteers
Metoclopramide is also used short-term to treat heartburn caused
When combined with 5-HT 3 antagonists there are reduced serotonin concentrations in the gut and increased sensitivity of 5-HT 3 receptors to antiemetics
Its use under these circumstances is both prophylactic and therapeutic
For example, irritable bowel syndrome and functional dyspepsia are two widespread conditions
5 In patients with chronic non-cancer pain, 80% of patients experience at least one adverse event, with constipation (41%), nausea (32%) and somnolence (29%) being most common 6
Most importantly, it acts as an antagonist of the dopamine D 2 receptor subtype
Mean bioavailability in healthy subjects, following administration of a single 8‑mg tablet, is approximately 56%
We describe a case of intestinal obstruction in a pregnant woman with severe nausea and vomiting of pregnancy treated with ondansetron, which is known to slow gut motility
The We will discuss here how serotonin forms and its role on gut motility, the factors that can fluctuate the level of serotonin in the gut, how SERT maintains serotonin level in the gut, which factors affect
0 mg/kg, IV or oral 30 min prior to administration of cancer drugs (Whitehead et al
In most countries, only two medications are approved or available for the treatment of gastroparesis: metoclopramide and domperidone
The effect of ondansetron on gut motility has been studied extensively in both man and animals and seems to have In the present study, ondansetron did not affect fasting, postprandial or 5-HT The effect of ondansetron on whole gut transit was assessed using the Weighed Average Position Score (WAPS) of the MRI marker capsules
18-23 We feel that it is more likely that the increase in fasting SBWC is due to reduced fasting small bowel motility